RxDoctor Payments Data

Janice Harada, MD

Internal Medicine · Honolulu, HINPI 1639271562

Payments from drug & device makers

$509in general payments, 2019–2025

Across 22 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$216
  • AbbVie$152
  • Novo Nordisk$43
  • Pfizer$33
  • AstraZeneca$27
  • Novartis$22
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$49798%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$509 in reported general payments places this provider in the 60th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$105,981
Medicare patients
333
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate61$92,757
JardianceEmpagliflozin44$73,295
OzempicSemaglutide46$71,775
TrulicityDulaglutide26$57,285
RybelsusSemaglutide11$28,822
XareltoRivaroxaban15$22,421
Atorvastatin Calcium573$20,001
MounjaroTirzepatide12$16,396
Rosuvastatin Calcium115$5,430
Amlodipine Besylate347$5,330
Ezetimibe61$4,660
Losartan Potassium224$4,646
Metformin Hcl ErMetformin Hcl196$4,608
Wixela InhubFluticasone Propion/Salmeterol41$4,320
Irbesartan97$4,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$43$100,59757 claims
Johnson & JohnsonXarelto$15$22,42115 claims
AbbVieSynthroid$152$2,65658 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →